Estimated glomerular filtration rate calculated by serum creatinine lacks precision and accuracy in adults with type 2 diabetes with preserved renal function.
Glomerular filtration rate
Kidney function
Type 2 diabetes
Journal
Journal of diabetes and its complications
ISSN: 1873-460X
Titre abrégé: J Diabetes Complications
Pays: United States
ID NLM: 9204583
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
03
06
2023
revised:
12
07
2023
accepted:
19
07
2023
medline:
5
9
2023
pubmed:
3
8
2023
entrez:
2
8
2023
Statut:
ppublish
Résumé
We evaluated the performance of creatinine-based equations that are currently used to estimate glomerular filtration rate (GFR) in people with type 2 diabetes compared to measured GFR using gold-standard methods. In this post-hoc analysis, 32 participants underwent repeated measurement of GFR by inulin clearance (mGFR). GFR was estimated by serum creatinine using the MDRD (eGFR At baseline, participants (38 % female) were age 60 ± 8 years, had diabetes duration of 9 ± 7 years, HbA1c 56 ± 9 mmol/mol (7.2 ± 0.8 %), and BMI 31.0 ± 6.2 kg/m In adults with type 2 diabetes and preserved renal function, eGFR equations underestimated mGFR, lacked precision and accuracy, and performance was lower at higher ranges of mGFR. Current eGFR equations by serum creatinine are inaccurate in adults with type 2 diabetes with preserved renal function, highlighting the necessity to develop new methods to measure kidney function at earlier stages of diabetic kidney disease.
Identifiants
pubmed: 37531756
pii: S1056-8727(23)00160-5
doi: 10.1016/j.jdiacomp.2023.108562
pii:
doi:
Substances chimiques
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108562Informations de copyright
Copyright © 2023. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: JAL has received speaker honoraria and/or consulting fees from Novo Nordisk, Boehringer Ingelheim, Merck, Eli Lilly, Prometric, and AstraZenca, and grant support from Merck, Novo Nordisk, and Sanofi. PB has received consulting fees and/or research support from Bayer, Bristol-Myers Squibb and Horizon Pharma. PB has received speaking honorarium from Boehringer Ingelheim-Eli. P.B. is on the scientific advisory board for XORTX. DZIC has received speaker honoraria from Janssen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Merck and has received research grant support from AstraZeneca, Merck, and Boehringer Ingelheim. BAP has received speaker honoraria from Medtronic, Johnson & Johnson, Roche, GlaxoSmithKline Canada, Novo Nordisk, and Sanofi; has received research grant support from Medtronic and Boehringer Ingelheim; and serves as a consultant for NeuroMetrix.